Alagille Syndrome Treatment Market, By Drug (Ursodeoxycholic Acid, Cholestyramine, Rifampicin, Late Stage Pipeline Drugs, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)

Published In : Oct 2023

Code : CMI4398

Pages :156

Formats :

Excel and PDF

Industry : Pharmaceutical

Market News

Global Alagille Syndrome Treatment Market: Key Developments

On June 2, 2023, CANbridge Pharmaceuticals, Inc., a global biopharmaceutical company, announced that the Chinese National Medical Products Administration (NMPA) has approved CAN108 (Maralixibat Chloride Oral Solution/LIVMARLI) to be marketed for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 1 year of age and older.

Global Alagille Syndrome Treatment Market: Key Trends

Approval and launch of new drugs for the treatment: The launch of drug in more than one region for the treatment of Alagille syndrome is expected to drive the growth of the global alagille syndrome treatment market over the forecast period. For instance, in December 2022, Mirum Pharmaceuticals, Inc., a biopharmaceutical company, announced that the European Commission has granted marketing authorization for LIVMARLI (maralixibat) oral solution for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) two months of age and older. The approval follows a positive opinion granted by the European Committee for Medicinal Products for Human Use (CHMP) in September 2022. LIVMARLI is the first and only approved treatment in both the European Union and the U.S. to treat this rare liver disease affecting one out of 30,000 people globally.